Free Papers
Automated clinical assessment of corneal guttae in Fuchs' endothelial corneal dystrophy
Free Paper Details
First Author: V.Kocaba THE NETHERLANDS
Co Author(s): Y. Soh G. Peh S. Naso J. Mehta
Abstract Details
Purpose:
To describe the validation and implementation of an automated system, for the detection and quantification of guttae in Fuchs Endothelial Corneal Dystrophy (FECD).
Setting:
Observational study performed at the Singapore National Eye Center.
Methods:
Patients with FECD underwent retroillumination corneal photography, followed by determination of the distributions and sizes of corneal guttae by an automated image analysis algorithm. Performance of the automated system was assessed via: a) validation against manual guttae segmentation, b) reproducibility studies to ensure consistency and c) evaluation for agreement with the Krachmer scale. It was then deployed to perform large-scale guttae assessment with anatomical subregion analysis in a batch of 40 eyes.
Results:
Compared to manual segmentation, the automated system was reasonably accurate in identifying the correct number of guttae (mean count of 78 guttae per 1x1mm test-frame, overestimation: +10 per frame), but had a tendency to significantly over-estimate guttae size (mean guttae size 1073 μm2, overestimation: +255 μm2). Automated measurements of guttae counts and sizes were reproducible within a 7.3 – 7.5% range across repeat assessments. Automated guttae counts, inter-guttae distances, and density of inter-guttae gaps lesser than 40 μm (i.e. D40 density) were highly correlated with the Krachmer scale (p inf to 0.001 for all). Large-scale guttae assessment demonstrated the automated system’s potential to selectively identify a region of the corneal endothelium most affected by densely packed guttae.
Conclusions:
Automated guttae assessment facilitates the precise identification and quantification of guttae characteristics in FECD patients. This can be utilized clinically as a personalized descemetorhexis zone for Descemet Stripping Only or Descemet Membrane Transplantation.
Financial Disclosure:
-